Genetics & Environmental Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genetics & Environmental Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Solid Cancer
Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results
November 22nd, 2007
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD), reported financial results for the third quarter ended September 30, 2007. Net loss for the third quarter of 2007 was $6.6 million compared to $16.7 million for the third quarter of 2006. "We remain focused on the development of our hypoxia-activated prodrug platform for the treatment of solid tumors and our ongoing development of glufosfamide," said Barry Selick, Threshold's chief executive officer. Research and development expenses were $4.9 million for the third quarter of 2007 versus $14.0 million for the third quarter of 2006. The decrease in research and development expenses reflects the...
Source: Genetics & Environmental Business Week (2007-11-22)
|
